dexamethasone injection

Mezigdomide-carfilzomib-dexamethasone provided a significant PFS benefit compared with carfilzomib-dexamethasone alone, with higher rates of grade 3 or 4 adverse events, including infections, which were mostly manageable with standard clinical practice and supportive care. These findings support mezigdomide-carfilzomib-dexamethasone as a clinically meaningful treatment option as early as first relapse in predominantly triple-class-exposed, anti-CD38 antibody-refractory and lenalidomide-refractory patients, a growing population with substantial unmet need.

P1/2, N=102, Completed, CHA University | Recruiting --> Completed

P3, N=40, Recruiting, Elsan | Not yet recruiting --> Recruiting

P=N/A, N=45, Completed, Saglik Bilimleri Universitesi

P=N/A, N=212, Not yet recruiting, Sir Run Run Shaw Hospital

P=N/A, N=60, Completed, Indonesia University | Recruiting --> Completed

P3, N=500, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2029 --> Dec 2029

P2, N=151, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: May 2025 --> Feb 2026

P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2028 --> Dec 2028

Exosomes were administered intravenously, while dexamethasone was given intraperitoneally...Their multi-modal mechanisms-including anti-inflammatory, anti-apoptotic, angiogenic, and neuroregenerative effects-highlight their potential as a novel therapeutic approach for stroke management. Future research should focus on clinical translation, dosage optimization, and long-term safety evaluation.

P1/2, N=70, Recruiting, The Methodist Hospital Research Institute | Not yet recruiting --> Recruiting

P4, N=176, Enrolling by invitation, University Medical Center Ho Chi Minh City (UMC)